L-carnitine Supplementation in Rheumatoid Arthritis Patients

Recruiting · NCT06753565 · Interventional (participants receive a specific treatment) · Lead sponsor: German University in Cairo

Interventions studied

CarnitineDisease-modifying anti-rheumatic drugs

This study aims to evaluate the effect of l-carnitine as add- on therapy for improving the outcome in rheumatoid arthritis patients.

Age range

18 Years to 60 Years

Sex

All (male and female)

Healthy volunteers

No - a diagnosis or condition is required

Phase

Phase 2

Study type

Interventional (participants receive a specific treatment)

age between 18-60 years old
diagnosed of rheumatoid arthritis according to 2010 American College of Rheumatology/European League Against Rheumatism criteria for at least 6 months
enrolled patients treated with one of more of conventional DMARDs for ≥ 6 months with stable dose for ≥ 1 month before start of the study
active RA despite conventional DMARDs treatment (DAS28 ESR more than or equal 3.2)
patient or legal representative should sign informed consent

pregnant or lactating female
patients with liver dysfunction (\>1.5x the upper limit of normal value for ALT \& AST)
Patients with kidney dysfunction (serum creatinine more than 1.2 mg/dl)
Patients with any active infection or concurrent malignancy
patients with uncontrolled medical conditions or other rheumatic diseases
patients currently taking drugs that could interact with carnitine like: warfarin

1 location listed.